Opioid Peptides Suppress HIV Activation in Immune Cells by Over 40%
Met-enkephalin, dynorphin, and kappa agonist U50,488 suppressed cytokine-induced HIV-1 expression by over 40% in chronically infected monocyte cells.
Quick Facts
What This Study Found
Met-enkephalin, dynorphin, and kappa agonist U50,488 suppressed IL-6-induced HIV-1 expression by over 40% in chronically infected monocyte cells.
Key Numbers
How They Did This
U1 promonocyte cells chronically infected with HIV-1 were treated with opioid agonists with or without IL-6 stimulation. HIV-1 expression was measured by p24 antigen levels.
Why This Research Matters
Understanding how opioid peptides affect HIV is important because many HIV patients use opioid drugs for pain. This study suggests opioids might actually suppress viral activation in some immune cells.
The Bigger Picture
Many HIV patients need opioid pain medications. This study suggests opioids might actually suppress HIV reactivation in some immune cells — a potentially beneficial effect that complicates the usual assumption that opioids are immunosuppressive.
What This Study Doesn't Tell Us
In vitro study using a single cell line. The U1 cell model does not represent all HIV-infected cell types. Effects in a living person with a complex immune system may differ greatly.
Questions This Raises
- ?Do opioid drugs in HIV patients affect viral rebound?
- ?Could kappa-selective opioids be developed as adjunct HIV therapy?
Trust & Context
- Key Stat:
- >40% HIV suppression Multiple opioid peptides suppressed cytokine-triggered HIV-1 expression in chronically infected monocytes
- Evidence Grade:
- Preliminary — in vitro single cell line study. Cannot predict effects in living HIV patients with diverse infected cell types.
- Study Age:
- Published in 1995 (31 years ago). The opioid-HIV interaction remains relevant as opioid use is common among HIV patients.
- Original Title:
- Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1.
- Published In:
- Advances in experimental medicine and biology, 373, 65-72 (1995)
- Authors:
- Chao, C C, Gekker, G, Sheng, W S, Hu, S, Portoghese, P S, Peterson, P K
- Database ID:
- RPEP-00318
Evidence Hierarchy
Frequently Asked Questions
Are opioids good or bad for HIV?
It's complicated. This study shows opioid peptides can suppress HIV activation in one type of immune cell. But other studies show opioids can suppress overall immune function. The net effect likely depends on which cells and which opioids are involved.
Does this mean HIV patients should take opioids?
No — this is an in vitro finding. But it suggests that for HIV patients who need opioid pain medications, the drugs might not be purely harmful to viral control, which is reassuring.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00318APA
Chao, C C; Gekker, G; Sheng, W S; Hu, S; Portoghese, P S; Peterson, P K. (1995). Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1.. Advances in experimental medicine and biology, 373, 65-72.
MLA
Chao, C C, et al. "Endogenous opioid peptides suppress cytokine-mediated upregulation of HIV-1 expression in the chronically infected promonocyte clone U1.." Advances in experimental medicine and biology, 1995.
RethinkPeptides
RethinkPeptides Research Database. "Endogenous opioid peptides suppress cytokine-mediated upregu..." RPEP-00318. Retrieved from https://rethinkpeptides.com/research/chao-1995-endogenous-opioid-peptides-suppress
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.